Valfixmed
Tel Aviv-Yafo · Founded 2019 · 1 known investors
VALFIX develops a transcatheter mitral valve repair system with a robotic interface, designed to convert open-heart valve surgery into a minimally invasive transcatheter procedure. The technology targets patients with mitral valve disease and heart failure.
Founders & leadership
PL
Philip LavinNamed on SEC filing
EY
Elad YaacobyNamed on SEC filing
EB
Eli BarNamed on SEC filing
Board
GG
Gary GershonyBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$1.1M disclosed across 1 round · 2018
▶$1.1MraisedOct 2019 · 12 investors · BiotechnologyRule 506(b)
▶$1.1MraisedOct 2019 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Philip LavinDirector
- Elad YaacobyDirector
- Eli BarExecutive Officer, Director
- Gary GershonyDirector
- Offering amount
- $1.7M
- Amount sold
- $1.1M
- Minimum investment
- $10K
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Valfixmed do?
- VALFIX develops a transcatheter mitral valve repair system with a robotic interface, designed to convert open-heart valve surgery into a minimally invasive transcatheter procedure. The technology targets patients with mitral valve disease and heart failure.
- Who are Valfixmed's investors?
- Valfixmed's investors include BayMed Venture Partners.
- How much funding has Valfixmed raised?
- Valfixmed has disclosed $1.1M raised across 1 round.
- Where is Valfixmed headquartered?
- Valfixmed is headquartered in Tel Aviv-Yafo.